Serious QT interval prolongation with ranolazine and amiodarone

Int J Cardiol. 2014 Mar 1;172(1):e60-1. doi: 10.1016/j.ijcard.2013.12.061. Epub 2013 Dec 28.

¹ Pharmacology, Therapeutics and Toxicology Department, UniversitatAutònoma de Barcelona, 08193 Bellaterra (Cerdanyola del Vallès), Spain. Electronic address: mtr@icf.uab.cat.
² Pharmacology, Therapeutics and Toxicology Department, UniversitatAutònoma de Barcelona, 08193 Bellaterra (Cerdanyola del Vallès), Spain; FundacióInstitutCatalà de Farmacologia, PasseigValld'Hebron 119-129, 08035 Barcelona, Spain; Catalan Centre of Pharmacovigilance, Barcelona, Spain.
³ Clinical Pharmacology Department, Hospital Universitari Germans TriasiPujol, Carretera de Canyet s/n, 08916 Badalona, Spain.
⁴ Pharmacology, Therapeutics and Toxicology Department, UniversitatAutònoma de Barcelona, 08193 Bellaterra (Cerdanyola del Vallès), Spain; Clinical Pharmacology Department, Hospital Universitari Germans TriasiPujol, Carretera de Canyet s/n, 08916 Badalona, Spain.
⁵ Pharmacology, Therapeutics and Toxicology Department, UniversitatAutònoma de Barcelona, 08193 Bellaterra (Cerdanyola del Vallès), Spain; FundacióInstitutCatalà de Farmacologia, PasseigValld'Hebron 119-129, 08035 Barcelona, Spain.

No abstract available

Keywords: Adverse drug reaction; Amiodarone; Angina; QT interval prolongation; Ranolazine.

Publication types